BIOVF (Swedish Orphan Biovitrum AB) Cyclically Adjusted Book per Share: $7.58 (As of Mar. 2026)


BIOVF Swedish Orphan Biovitrum AB BIOVF
88 GF Score
Price $48.00
GF Value $34.48
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Cyclically Adjusted Book per Share?

Swedish Orphan Biovitrum AB BIOVF 88 Cyclically Adjusted Book per Share is $7.58 as of Mar. 2026. GuruFocus rates BIOVF with a GF Score™ of 88/100 and a GF Value™ of $34.48 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted book value per share for the three months ended in Mar. 2026 was $12.530. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.58 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Swedish Orphan Biovitrum AB's average Cyclically Adjusted Book Growth Rate was 13.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 17.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Swedish Orphan Biovitrum AB was 24.50% per year. The lowest was 13.00% per year. And the median was 19.55% per year.

As of today (2026-07-04), Swedish Orphan Biovitrum AB's current stock price is $48.00. Swedish Orphan Biovitrum AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $7.58. Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio of today is 6.33.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Swedish Orphan Biovitrum AB was 13.83. The lowest was 3.88. And the median was 5.58.


Swedish Orphan Biovitrum AB  (OTCPK:BIOVF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=48.00/7.58
=6.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Swedish Orphan Biovitrum AB was 13.83. The lowest was 3.88. And the median was 5.58.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Swedish Orphan Biovitrum AB Cyclically Adjusted Book per Share Related Terms


Swedish Orphan Biovitrum AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Cyclically Adjusted Book per Share Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.94 4.57 5.30 5.51 7.64

Swedish Orphan Biovitrum AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.53 6.91 7.34 7.64 7.58

BIOVF vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted PB Ratio falls into.


BIOVF
88GF Score
Swedish Orphan Biovitrum AB BIOVF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=12.53/133.5600*133.5600
=12.530

Current CPI (Mar. 2026) = 133.5600.

Swedish Orphan Biovitrum AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.246 101.019 2.969
201609 2.237 101.138 2.954
201612 2.071 102.022 2.711
201703 2.229 102.022 2.918
201706 2.440 102.752 3.172
201709 2.815 103.279 3.640
201712 2.832 103.793 3.644
201803 3.106 103.962 3.990
201806 3.165 104.875 4.031
201809 3.365 105.679 4.253
201812 3.543 105.912 4.468
201903 5.061 105.886 6.384
201906 5.168 106.742 6.466
201909 5.248 107.214 6.538
201912 5.825 107.766 7.219
202003 6.150 106.563 7.708
202006 6.478 107.498 8.049
202009 6.871 107.635 8.526
202012 7.826 108.296 9.652
202103 7.910 108.360 9.750
202106 8.161 108.928 10.006
202109 8.141 110.338 9.854
202112 8.261 112.486 9.809
202203 8.038 114.825 9.349
202206 7.828 118.384 8.832
202209 7.414 122.296 8.097
202212 8.247 126.365 8.717
202303 8.554 127.042 8.993
202306 8.476 129.407 8.748
202309 9.151 130.224 9.385
202312 9.718 131.912 9.839
202403 10.142 132.205 10.246
202406 10.116 132.716 10.180
202409 10.559 132.304 10.659
202412 10.678 132.987 10.724
202503 11.215 132.825 11.277
202506 11.871 133.699 11.859
202509 11.137 133.480 11.144
202512 11.741 133.390 11.756
202603 12.530 133.560 12.530

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $7.58 mean?
Swedish Orphan Biovitrum AB (BIOVF) has a Cyclically Adjusted Book per Share of $7.58 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's Cyclically Adjusted Book per Share too high?
Swedish Orphan Biovitrum AB's current Cyclically Adjusted Book per Share is $7.58. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Swedish Orphan Biovitrum AB's Cyclically Adjusted Book per Share of $7.58 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Cyclically Adjusted Book per Share is $7.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (BIOVF) is currently considered Significantly Overvalued. The stock's GF Value™ is $34.48, compared to a current price of $48.00 — trading 39.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is $7.58. Swedish Orphan Biovitrum AB's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (BIOVF), the current Cyclically Adjusted Book per Share is $7.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $48.00 is trading 39.2% above its estimated GF Value™ of $34.48. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for BIOVF:

  • Cyclically Adjusted Book per Share: $7.58
  • GF Value™: $34.48 vs. price of $48.00 (39.2% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
88GF Score

Get the complete analysis for BIOVF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.00
Price
$34.48
GF Value